All News
For a drug that everything in RA has been built on, we're not great at predicting who will respond to methotrexate.
It's probably because we don't have all the info. Adding pharmacogenomics increased optimal AI prediction from 55% to 76%
@MayoClinic FRI0046 #EULAR2020 @RheumNow https://t.co/bwpSYQIBLG
David Liew drdavidliew ( View Tweet)
Filgo reduces PsA markers OP0224. ? Unique to filgo, a JAK1 effect , class effect or part of any effective PsA Rx or some of the above? @eular_org @RheumNow @CRASCRRheum @earlyarthritis #EULAR2020 https://t.co/2O5wsLPNl2
Janet Pope Janetbirdope ( View Tweet)
To truly address adherence, you need to understand what is impairing it, and tailor an approach to overcome those barriers.
Great to see this articulated in EULAR recommendations re: non-adherence - a big factor in our therapeutic outcomes!
EULAR projects #EULAR2020 @RheumNow https://t.co/0pazcDFTuV
David Liew drdavidliew ( View Tweet)
#EULAR2020 OP0019 DON'T STOP TNFi in RA remission per ARCTIC-REWIND trial: RCT X 1 year n=99 multicenter gov't funded- DAS28 remission X1 year, dz X10 yrs, 2/3 pts (RF+/CCP+), no doppler signal.
Results: 63% flared who had TNFi w/drawn vs. 5% when TNFi continued @RheumNow https://t.co/SsR1vUGbOe
k dao KDAO2011 ( View Tweet)
Analysis of the UK THIN database shows that delays in receiving followup Denosumab injx results in higher fracture risk (vertebral & Maj OP Fx). 6144 infusions in 2594 pts, shows risk if delay is >16wks (long delay), but not if 4-16wks #EULAR20 SAT0453 https://t.co/DkJK3dHeRN https://t.co/r7ckpSF6PA
Links:
Dr. John Cush RheumNow ( View Tweet)
H2H UPA vs ABA RCT; UPA is clinically superior to ABA in DAS-CRP remission, ACR50, ACR70 at wk 12/24 (NOT diff in Pain, FACIT, Boolean remission); But UPA has more serious AE (vs ABA) - esp hepatic, OI, SIE, SAE, CPK (but not zoster VTE) #EULAR20 SAT0151 https://t.co/K96lybdg7L https://t.co/vQM2MSCNzD
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr Mariette summarizes the evidence for using cytokine-targeted therapies in #COVIDー19
Several studies with favorable results with #Tocilizumab and #Anakinra, however, almost all with methodological limitations (e.g., historical groups)
#EULAR2020 #EULAR20 #EULAR2020goesvirtual https://t.co/cMUKoeGfK9
Juan Camilo Sarmiento-Monroy jcsam25 ( View Tweet)
VTE elevated risk is assoc up to 1 yr after high disease activity in RA 1% over 1 yr of active RA will get VTE OP0034 Data from Swedish popn study implications irrespective for which Rx pt gets? @eular_org @RheumNow @CRASCRRheum @earlyarthritis #EULAR20 #eular2020 https://t.co/A7mWoYZI9S
Janet Pope Janetbirdope ( View Tweet)
JAKi and VTE from @WHO VigiBase @UMCGlobalSafety
Why the difference between Europe and US?
There may be a class effect here (there may not be), but if we really want real-world answers we need effective systematic real-world data collection
OP0237 #EULAR2020 @RheumNow https://t.co/Bh2iLpGdXM
David Liew drdavidliew ( View Tweet)
MAINRITSAN3 RCT, RTX v PLBO in AAV
28mo relapse free survival ⬇️ RTX (96% vs 74%, NNT~4), majr (100% vs 87%, NNT~8)
1. Selected grp (all pts from MAINRITSAN2)
2. All pts had GC q3mos - IRL benefit could be bigger?
Strong data for RTX >2yrs in AAV
PDF: https://t.co/Mbrq7bFHk0 https://t.co/auKJ3QPKr0
Mike Putman EBRheum ( View Tweet)
Filgotinib was associated with significant reduction in SIJ erosion scores in axSpA: imaging data from the double-blind, randomized Tortuga trial #EULAR2020 @rheumnow THU0377 https://t.co/1b18Uyvo5j https://t.co/zBXCwGc0Q7
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Integrated safety analysis of filgotinib treatment for RA from 7 clinical trials: 4,057 patients, VTE risk looks very reassuring #EULAR2020 @RheumNow https://t.co/Ld2tpu7UT5 https://t.co/sZqadeUTh8
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Secukinumab in nr-axSpA, in a mostly biologic naive cohort was effective: ASAS40 response of ~42%, data from the Phase III prevent trial Abstract OP0106 #EULAR2020 @rheumnow https://t.co/KATpGJs2y9 https://t.co/zeBFS2pMl0
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
And another one! No association of MTX with worsening of ILD in this study by Men-Vazquez et al. #EULAR2020 https://t.co/X7C6KyC29L
Richard Conway RichardPAConway ( View Tweet)
#Eular2020 #op0224 filgotinib successfully reduces levels of circulating biomarkers in PsA suggestive of clinical efficacy: CRP&SAA >50%, IL6, CXCL10&IL23 >25%. Also decreased ICAM1,VCAM1, MMP1&SC1M @RheumNow
Olga Petryna DrPetryna ( View Tweet)
Enticing stuff. Avacopan wins on 52w remission, steroid toxicity/use, renal fx, with minimal toxicity.
Looks good to be a steroid replacement in AAV, with real benefit for patients. Exciting but cost will dictate if we get to use it (see: apremilast) OP0011 #EULAR2020 @RheumNow https://t.co/WTFk21D0KY
David Liew drdavidliew ( View Tweet)
#EULAR2020 ABST#OP0012 German RABBIT registry show TNFi has less risk for venothrombolic events HR 0.53 (95% CI 0.33-0.86) compared to csDMARD in RA. Age > 65 years, CRP > 5 mg/L increases risk for VTE, no differences with steroids or smoking status.
@RheumNow https://t.co/Hkv6T7pl9f
k dao KDAO2011 ( View Tweet)
#EULAR2020 ABST#OP0014 Plenary session: Secukinumab and etanercept do NOT work for anterior uveitis in SpA based on Swedish Rheum Quality Registry of > 2600 patients @rheumnow https://t.co/2kJ3b4JObq
k dao KDAO2011 ( View Tweet)
#EULAR2020 Abstr#LB001 Coming soon...another indication for @Rinvoq? Favorable response in phase III trial of upadacitinib vs. ADA vs. PCB for PsA (SELECT-PsA-1) @abbvie @rheumnow https://t.co/0udmPlR2pQ
k dao KDAO2011 ( View Tweet)
#EULAR2020 OP0020: RABBIT 5500 pt study of all DMARDS/biologics, IL-6 inh may be the best to improve fatigue seen in RA patients @rheumnow https://t.co/VJW8MwMamM
k dao KDAO2011 ( View Tweet)
